AG
RNAC icon

Artal Group’s Cartesian Therapeutics RNAC Stock Holding History

Artal Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-304,554
Closed -$8.23M – 79
2024
Q2 		$8.23M Sell
304,554
-1
-0% -$24 0.21% 44
2024
Q1 		$5.94M Hold
304,555
– – 0.15% 59
2023
Q4 		$6.3M Hold
304,555
– – 0.21% 44
2023
Q3 		$9.69M Hold
304,555
– – 0.42% 37
2023
Q2 		$10.2M Buy
304,555
+141,782
+87% +$5.07M 0.32% 48
2023
Q1 		$6.79M Hold
162,773
– – 0.4% 53
2022
Q4 		$5.52M Hold
162,773
– – 0.31% 59
2022
Q3 		$8.01M Hold
162,773
– – 0.34% 49
2022
Q2 		$6.4M Buy
162,773
+29,440
+22% +$873K 0.34% 47
2022
Q1 		$4.92M Hold
133,333
– – 0.21% 80
2021
Q4 		$13M Hold
133,333
– – 0.35% 60
2021
Q3 		$16.6M Hold
133,333
– – 0.37% 61
2021
Q2 		$16.7M Sell
133,333
-16,667
-11% -$1.98M 0.34% 63
2021
Q1 		$20.4M Hold
150,000
– – 0.36% 65
2020
Q4 		$13.6M Hold
150,000
– – 0.29% 78
2020
Q3 		$11.2M Buy
150,000
+53,333
+55% +$4.09M 0.27% 73
2020
Q2 		$8.24M Sell
96,667
-17,121
-15% -$1.55M 0.23% 78
2020
Q1 		$8.23M Hold
113,788
– – 0.35% 55
2019
Q4 		$8.12M Buy
113,788
+43,788
+63% +$2.11M 0.31% 54
2019
Q3 		$3.67M Hold
70,000
– – 0.15% 82
2019
Q2 		$3.76M Hold
70,000
– – 0.15% 86
2019
Q1 		$4.98M Buy
70,000
+50,000
+250% +$3.17M 0.2% 76
2018
Q4 		$1.6M Buy
20,000
+1,282
+7% +$293K 0.06% 97
2018
Q3 		$8.73M Buy
18,718
+2,051
+12% +$824K 0.23% 60
2018
Q2 		$6.63M Buy
16,667
+12,500
+300% +$4.43M 0.14% 59
2018
Q1 		$1.27M Buy
+4,167
New +$1.19M 0.02% 100

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group's RNAC Position: Q3 2024 in Review

Artal Group sold out of Cartesian Therapeutics (RNAC) in Q3 2024, closing a stake of 304,554 shares — an estimated $8.23M sold.

Artal Group first reported a position in RNAC in Q1 2018 and held it in 26 quarters. The position peaked at $20.4M in Q1 2021. 64 funds tracked by Wall St. Rank hold RNAC as of Q3 2024.

  • Artal Group reported no remaining Cartesian Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 304,554 Cartesian Therapeutics shares in Q3 2024, an estimated $8.23M.
  • Artal Group first reported a position in Cartesian Therapeutics in Q1 2018 and held it in 26 quarters.
  • Artal Group's Cartesian Therapeutics position peaked at $20.4M in Q1 2021.
  • 64 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.